Skip to main content
Premium Trial:

Request an Annual Quote

Following Nanogen Investment, Jurilab Says it Expects Additional Funding from Undisclosed Parties

NEW YORK, July 26 (GenomeWeb News) - Jurilab expects several million dollars worth of additional funding from undisclosed parties within the next several months, on top of the $3 million investment from Nanogen announced on Tuesday, GenomeWeb News has learned.

 

Nanogen has so far invested $1.5 million in the Finnish pharmacogenomics company, giving it an approximately 20-percent equity interest in Jurilab, and will add another $1.5 million within six months.

 

As a result of the expected additional funding, Nanogen's equity interest in Jurilab after the second investment tranche will total less than 25 percent, not close to 40 percent as previously reported, according to a company spokesperson.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.